InvestSMART

Percheron Therapeutics Limited (ASX:PER)

ALERT: Price-sensitive ASX Announcement for PER
Current share price for PER : $0.005 0.002 (50%)+
Announcement
Release
10 Aug 2026 8:24AM
Price at Release
$0.003
Full Release
download
Summary
On August 10, 2026, Percheron Therapeutics Limited, a biotechnology company based in Melbourne, announced a CEO succession. Dr. James Garner, the current CEO since August 2023, is stepping down to pursue new opportunities overseas and will remain in his role until August 31, 2026. Dr. Michael Baker will succeed him as CEO and Managing Director effective October 5, 2026. Dr. Baker, who played a pivotal role in transforming Arovella Therapeutics, will receive a remuneration package with a significant focus on equity aligned with shareholder interests. Dr. Garner will continue on the Board as a Non-Executive Director to support Dr. Baker's transition and ensure continuity. The company is preparing to start a new clinical trial for its HMBD-002 program by the second half of the calendar year 2026.
Key Points
  • Dr. James Garner to step down as CEO effective August 31, 2026.
  • Dr. Michael Baker appointed as new CEO effective October 5, 2026.
  • Dr. Garner to remain on the Board as a Non-Executive Director.
  • Dr. Baker’s remuneration includes equity components tied to performance.
  • Percheron Therapeutics remains on track for new clinical trials in 2026.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.